The MyPathway trial, a multi-basket study, included HER2-overexpressing or amplified biliary tract cancers and reported a median OS of 12.9 months, an ORR of 30.6%, with a median PFS of 4.7 months [78]. This evidence concerns the gene ERBB2 and biliary tract cancer.